AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06281665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive similar appearing placebo daily for 6 months.
Trial: NCT05824923
Drug: Guideline-directed medical therapy (GDMT) for heart failure
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDMT medication recommendation including:~* Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~* Beta-receptor blocker (BB)~* Mineralocorticoid receptor antagonist (MRA)~* Sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2023 ESC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 12-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion.
Trial: NCT04681833
Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Repeat Dose
Trial: NCT04681833
Drug: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)
RxNorm normalized name: respiratory syncytial virus vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Repeat Dose/High Repeat Multiple Dose
Trial: NCT04681833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid diluent/Lyophilised Powder
Trial: NCT04877275
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 intravenously on day 1 , QW
Trial: NCT04930549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo tablets once a day during 12 weeks
Trial: NCT04877275
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide：300mg/m2, d1 QW，
Trial: NCT05926349
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per the label of the chosen usual care product(s) and/or usual care standards.
Trial: NCT05634746
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally disintegrating tablet.~Other Names:~PBO
Trial: NCT05082051
Drug: Part B
RxNorm normalized name: Hem-Care Premium 7-Part Blend Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after multiple oral dose administration in healthy adult subjects.~It will evaluate multiple dose administration of CDX-7108 at an appropriate low (50 000 lipase units), mid (150 000 lipase units), and high dose (250 000 lipase units) 4 times a day (QID) for 6 consecutive days in 3 sequential cohorts of 6 subjects each.
Trial: NCT06490653
Drug: Blood Stopper (Ankaferd)
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
Trial: NCT06606093
Drug: DWP16001 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, Orally, Once daily single dose
Trial: NCT06606093
Drug: DWP16001 0.3mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, Orally, Once daily single dose
Trial: NCT06608056
Drug: Pain management after surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.
Trial: NCT06606821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
Trial: NCT06606015
Drug: I.V Paracetamol.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological thereby for hsPDA closure in the preterm neonates.
Trial: NCT04854044
Drug: Akt/ERK Inhibitor ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT06239441
Drug: IL5/IL5R Antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with IL5/IL5R antagonists for one year
Trial: NCT04309877
Drug: Theophylline ER
RxNorm normalized name: Theophylline ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of theophylline ER
Trial: NCT06379958
Drug: leramistat 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT06379958
Drug: Phenytoin 100 Mg Oral Capsule
RxNorm normalized name: phenytoin 100 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT06379958
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT04703608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-identical placebo
Trial: NCT05730543
Drug: Volbella or Juvederm Ultra XC filler
RxNorm normalized name: Hongo Killer Ultra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid filler
Trial: NCT06305715
Drug: Targeted TKI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately following radiation therapy, subjects with an actionable driver mutation will receive a standard-of-care TKI. The choice of TKI will be at the discretion of the treating oncologist.
Trial: NCT05142254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
Trial: NCT06017921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
Trial: NCT04705597
Drug: BGE-175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT06040203
Drug: Placebo (saline solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
Trial: NCT05308472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, once a day for 120 days
Trial: NCT05641428
Drug: ARI-0001
RxNorm normalized name: OVIS ARIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
Trial: NCT04694755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards
Trial: NCT04694755
Drug: Traditional Chinese medicine prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianjiang brand formula granules, in line with GMP standards
Trial: NCT05728788
Drug: Antitumor drugs
RxNorm normalized name: SHIITAKE MUSHROOM 15 g in 100 g ORAL LIQUID [SALANA 153 (Blood circulation, Cytothesis, Thrombolysis, Immunity boost, An antitumor, Antiinflammatory, Regulatory action, Inhibitory action, Exocytosis)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracyclines, immune checkpoint inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors
Trial: NCT06607887
Drug: IV antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.
Trial: NCT06607887
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.
Trial: NCT05440006
Drug: Fuzuloparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzuloparib Capsules; 150mg; single dose per cycle.
Trial: NCT04788797
Drug: Prolyl Endopeptidase
RxNorm normalized name: Prolyl endopeptidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules three times a day.
Trial: NCT05417269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered by subcutaneous route, once every two weeks for 6 times. Placebo will be administered to patients randomized in the placebo group during Phase II only.
Trial: NCT04384601
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy will be administered according to description in two arms.
Trial: NCT00027365
Drug: AS02A Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06279104
Drug: physician's choice of chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
Trial: NCT04713904
Drug: Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Medicinal Product
Trial: NCT04713904
Drug: Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evafem 20 (Trademark)
Trial: NCT06344052
Drug: SP-002
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration
Trial: NCT05683574
Drug: FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
Trial: NCT05683574
Drug: etoricoxib 90 mg (Arcoxia®) +FDC placebo
RxNorm normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
Trial: NCT05683574
Drug: cyclobenzaprine hydrochloride + etoricoxib placebo
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
Trial: NCT04863248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
Trial: NCT05108025
Drug: Topical Powder
RxNorm normalized name: Topical Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Powder mixed with diluent
Trial: NCT05108025
Drug: Placebo Topical Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Topical Powder mixed with diluent
Trial: NCT06605963
Drug: PPV-06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
Trial: NCT05447702
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion.
Trial: NCT06605963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
Trial: NCT00377546
Drug: Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00377546
Drug: Ketorolac LS, Bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03641248
Drug: Enteric coated Devil's Claw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
Trial: NCT03641248
Drug: Non-enteric coated Devil's Claw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
Trial: NCT06065059
Drug: TNG348
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquitin Specific Peptidase 1 (USP1) inhibitor
Trial: NCT05122260
Drug: Q-Griffithsin
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal spray administered as a single dose
Trial: NCT04895293
Drug: RBM-007 Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution
Trial: NCT05211804
Drug: Ophthalmic Drugs
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the same treatment as if not a part of the project
Trial: NCT04480190
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusional 5-FU 225 mg/m2/d via Continuous IV infusion, to be given Days 1-5 and 8-12 during RT
Trial: NCT05126264
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: morning and afternoon
Trial: NCT05126264
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: morning, afternoon and night
Trial: NCT04829799
Drug: Phenylephrine 1.0%/ Ketorolac 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
Trial: NCT05848700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet
Trial: NCT05946785
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
Trial: NCT05159895
Drug: [14C]-DZD9008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration
Trial: NCT05068063
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
Trial: NCT04656041
Drug: FOLFOX/ nal-IRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2) Oxaliplatin via IV, predetermined dosage per protocol~* 3) Leucovorin via IV, predetermined dosage per protocol~* 4) 5-Fluorouracil via IV, predetermined dosage per protocol
Trial: NCT04942340
Drug: Atipamezole & Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
Trial: NCT03843385
Drug: encapsulated faecal microbiota filtrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
Trial: NCT03843385
Drug: encapsulated faecal microbiota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
Trial: NCT03843385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline encapsulated in hypromellose capsules and frozen.
Trial: NCT06289920
Drug: BR3005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone, Once a day
Trial: NCT06289920
Drug: BR3005-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone, Once a day
Trial: NCT06289920
Drug: BR3005-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone, Once a day
Trial: NCT05055258
Drug: KVD824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KVD824 300 mg Modified-Release Tablets
Trial: NCT05055258
Drug: Placebo to KVD824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to KVD824 300 mg Modified-Release Tablets
Trial: NCT06121141
Drug: Full strength lidocaine with epinephrine
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with epinephrine 1:100,000
Trial: NCT06121141
Drug: Dilute lidocaine with epinephrine
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with epinephrine 1:100,000 diluted with normal saline (09.% NaCl) in a 1:4 ratio
Trial: NCT06474507
Drug: Calculus bovis sativus (CBS)
RxNorm normalized name: Mycobacterium bovis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.
Trial: NCT06669117
Drug: VERT-002
RxNorm normalized name: Wal-vert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of Administration: Intravenous
Trial: NCT06399185
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
Trial: NCT06607861
Drug: saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebulization of 4 mL 0.9% saline twice daily
Trial: NCT05363293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo formulation
Trial: NCT06126952
Drug: Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sprays per nostril of Placebo twice daily.
Trial: NCT05256342
Drug: Etoricoxib 60 mg
RxNorm normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill daily for 8 weeks
Trial: NCT06455410
Drug: GP
RxNorm normalized name: GPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine + cisplatin
Trial: NCT06455410
Drug: concurrent chemoradiotherapy (CCRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concurrent chemoradiotherapy (CCRT)
Trial: NCT05327361
Drug: Liftactiv B3
RxNorm normalized name: VITAMIN B3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will apply a dime size amount of the serum to 1 side of the face.
Trial: NCT04900337
Drug: AMOR 18 Powder & Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
Trial: NCT04900337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
Trial: NCT06508645
Drug: DWP14012 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)
Trial: NCT06099418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
Trial: NCT00002319
Drug: Doxorubicin hydrochloride (liposomal)
RxNorm normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05985278
Drug: [ Lu-177]-Catalase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
Trial: NCT06607926
Drug: Thymosin Alpha 1
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 mg subcutaneous injection twice weekly over 12 weeks
Trial: NCT06194955
Drug: GIP(1-42)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT04644796
Drug: saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
Trial: NCT04782245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
Trial: NCT04709484
Drug: USG-guided steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.